SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).

被引：9
|
作者：
Lowe, Elizabeth S.
Jayawardene, Deepthi
Penson, Richard T.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5598
引用
收藏
页数：3
相关论文
共 50 条
  • [21] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
    Tucker, Helen
    Charles, Zoe
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
  • [22] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
    Tutt, Andrew Nicholas James
    Kaufman, Bella
    Gelber, Richard D.
    Mc Fadden, Eleanor
    Goessl, Carsten Dietrich
    Viale, Giuseppe
    Arahmani, Amal
    Fumagalli, Debora
    Azim, Hatem Abdel
    Wu, Wenting
    Grocholewicz, Anna
    Costantino, Joseph P.
    Rastogi, Priya
    Garber, Judy Ellen
    Geyer, Charles E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Tutt, A.
    Kaufman, B.
    Garber, J.
    Gelber, R.
    McFadden, E.
    Goessl, C.
    Viale, G.
    Geyer, C.
    Zardavas, D.
    Arahmani, A.
    Fumagalli, D.
    De Azambuja, E.
    Ponde, N.
    Herbolsheimer, P.
    Wu, W.
    Constantino, J.
    Rastogi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
    Gao, Qinglei
    Zhu, Jianqing
    Zhao, Weidong
    Huang, Yi
    An, Ruifang
    Zheng, Hong
    Qu, Pengpeng
    Wang, Li
    Zhou, Qi
    Wang, Danbo
    Lou, Ge
    Wang, Jing
    Wang, Ke
    Low, John
    Kong, Beihua
    Rozita, Abdul Malik
    Sen, Lim Chun
    Yin, Rutie
    Xie, Xing
    Liu, Jihong
    Sun, Wei
    Su, Jingya
    Zhang, Chunyi
    Zang, Rongyu
    Ma, Ding
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2278 - 2285
  • [25] SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pis) with ovarian cancer and a BRCA1/2 Imitation (BRCAm)
    Moore, Kathleen N.
    DiSilvestro, Paul
    Lowe, Elizabeth S.
    Garnett, Sally
    PuJade-Laurains, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design
    Poveda, Andres M.
    Davidson, Richard
    Blakeley, Christopher
    Milner, Alvin
    FUTURE ONCOLOGY, 2019, 15 (32) : 3651 - 3663
  • [27] Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2021, 22 (05): : 620 - 631
  • [28] Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (09) : 535 - 536
  • [29] Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
    Cheng, Li-Jen
    Wong, Grace
    Chay, Wen-Yee
    Ngeow, Joanne
    Tan, Yongqiang
    Soon, Swee Sung
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 441 - 448
  • [30] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
    Ledermann, Jonathan A.
    Lortholary, Alain
    Penson, Richard T.
    Gibbs, Emma
    Provencher, Diane M.
    Bruchim, Ilan
    Huzarski, Tomas
    Barretina-Ginesta, Maria Pilar
    Sabbatini, Roberto
    Mileshkin, Linda R.
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Matsumoto, Koji
    Sonke, Gabe S.
    Mikheeva, Olga N.
    Kim, Jae-Weon
    Girotto, Gustavo Colagiovanni
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345